Hermetica Superfood Encyclopedia
The Short Answer
Trametes hirsuta contains β-glucans, phenolic compounds, and flavonoids that exert antioxidant activity through free radical scavenging and immunomodulatory effects via polysaccharide-mediated immune cell activation. In vitro studies demonstrate that T. hirsuta extracts inhibit MCF-7 breast cancer cell proliferation at rates of 92.3% and 81.0% for two distinct extract fractions, outcomes exceeding those of a 0.1 mM cisplatin positive control in the same assay.
CategoryMushroom
GroupMushroom/Fungi
Evidence LevelPreliminary
Primary KeywordTrametes hirsuta benefits
Hairy Bracket Fungus — botanical close-up
Health Benefits
**Immunomodulatory Activity**: β-Glucans present in T
hirsuta biomass, reported at approximately 42% content in related Trametes species extracts, activate pattern recognition receptors such as Dectin-1 on macrophages and dendritic cells, promoting innate immune responses and cytokine production.
**Antioxidant Protection**
High phenolic and flavonoid content in ethanolic extracts enables electron donation and hydrogen atom transfer to neutralize reactive oxygen species, as validated by DPPH free radical scavenging assays in vitro, consistent with phenolic-rich Trametes extracts showing strong radical quenching capacity.
**Anticancer Potential**: Two distinct T
hirsuta extract fractions (7-ME and 9-ME) demonstrated 92.3% and 81.0% inhibition rates respectively against MCF-7 human breast adenocarcinoma cells in vitro, surpassing cisplatin reference control activity in the same experimental model.
**Antispasmodic Effects**: Ethanolic extract of T
hirsuta at 300 mg/kg body weight exhibited 59.43% antispasmodic activity in an animal model, approaching the 65.21% activity of the reference drug buscopan (hyoscine butylbromide), suggesting smooth muscle relaxation properties.
**Antibacterial Activity**: T
hirsuta extracts demonstrate significant inhibitory activity against Staphylococcus aureus, a clinically relevant gram-positive pathogen, likely mediated through disruption of cell membrane integrity and inhibition of bacterial metabolic enzymes by phenolic constituents.
**Ligninolytic Enzyme Production**: T
hirsuta produces laccase, manganese peroxidase, and other oxidoreductase enzymes during wood degradation; these enzymes have demonstrated biotechnological relevance and potential pharmaceutical applications in oxidative stress research models.
**Anti-inflammatory Potential**: The flavonoid and polyphenolic profile of T
hirsuta is structurally consistent with compounds known to inhibit pro-inflammatory mediators such as NF-κB signaling and COX enzyme pathways, though direct mechanistic confirmation in T. hirsuta-specific studies remains pending.
Origin & History
Natural habitat
Trametes hirsuta is a saprotrophic polypore fungus distributed across temperate and subtropical regions worldwide, including Europe, Asia, North America, and parts of Africa, where it colonizes dead or dying hardwood trees such as oak, beech, and willow. It thrives in humid forest environments, growing as a shelf-like bracket fruiting body on decaying wood, and plays an essential ecological role in lignocellulose decomposition via its white-rot enzymatic machinery. Modern research specimens are frequently obtained through submerged liquid fermentation cultivation techniques, which allow controlled biomass production for standardized extract preparation.
“Trametes hirsuta does not feature prominently in historical ethnomycological records or codified traditional medicine systems such as Traditional Chinese Medicine or Ayurveda, in contrast to its close relative Trametes versicolor (Yun Zhi), which has centuries of documented use in East Asian medicine. The broader genus Trametes has been used informally in folk medicine traditions in parts of Eastern Europe and East Asia for general wellness, though T. hirsuta-specific preparation records are not well-documented in the ethnobotanical literature. Modern scientific interest in T. hirsuta has emerged primarily from its biotechnological relevance as a white-rot fungus producing industrially valuable laccases and ligninolytic enzymes, with medicinal research being a secondary and more recent development. Its hairy, bracket-shaped fruiting body has made it a recognizable species among amateur mycologists and foragers in temperate woodlands, though it is not traditionally consumed as a food mushroom due to its tough, corky texture.”Traditional Medicine
Scientific Research
The current evidence base for Trametes hirsuta is exclusively preclinical, comprising in vitro cell culture experiments and acute animal pharmacology studies, with no published human clinical trials identified in the peer-reviewed literature. In vitro anticancer studies demonstrated striking inhibition of MCF-7 breast cancer cell proliferation (92.3% and 81.0% for two extract fractions), though these results require validation in animal tumor models and eventual clinical translation before efficacy claims can be made. An animal model antispasmodic study reported 59.43% activity at 300 mg/kg ethanolic extract, providing a preliminary pharmacodynamic signal but offering limited translatability to human dosing due to interspecies differences and the absence of pharmacokinetic data. The overall volume of species-specific research on T. hirsuta is sparse compared to related species such as Trametes versicolor, and the field requires controlled in vivo studies, mechanistic characterization of isolated bioactive fractions, and ultimately randomized controlled trials to substantiate its therapeutic potential.
Preparation & Dosage
Traditional preparation
**Ethanolic Extract (Research Form)**
150–300 mg/kg body weight; no validated human equivalent dose has been established from clinical data
Animal studies employed doses of .
**Aqueous Decoction**
Traditional preparation involves boiling dried fruiting body material in water for 20–40 minutes; no standardized concentration or dosing protocol is defined for T. hirsuta specifically.
**Submerged Fermentation Biomass Extract**
Laboratory and biotechnological production uses submerged liquid cultivation to generate standardized biomass containing approximately 42% β-glucan content (reported for related Trametes sp. biomass extracts).
**Dried Fruiting Body Powder**
500–1000 mg per serving, though no species-specific standardization exists for T
Related Trametes species supplements are commonly encapsulated at . hirsuta.
**Standardization Note**
No pharmacopoeial or industry standardization for β-glucan or polyphenol content has been established for T. hirsuta commercial products; consumers should reference certificates of analysis and request independent third-party testing.
**Timing**
No clinical data exists to recommend specific administration timing; general mushroom supplement guidance suggests consumption with meals to improve gastrointestinal tolerability.
Nutritional Profile
Trametes hirsuta fruiting bodies, consistent with other woody polypore fungi, contain primarily structural polysaccharides including β-(1,3)/(1,6)-glucans, which constitute a significant portion of the dry biomass and represent the key immunologically active macromolecular fraction. Phenolic compounds including gallic acid, protocatechuic acid, and various flavonoids are concentrated in ethanolic extracts, while the aqueous fraction is enriched in polysaccharides; total phenolic content in related Trametes species ethanolic extracts has been quantified at approximately 48.71 mg/g dry weight with flavonoid content around 13.13 mg/g. Minor constituents documented in Trametes genus biomass include saponins (approximately 70.6 µg/mL in fermentation extracts) and anthraquinones (approximately 14.5 µg/mL), alongside trace minerals, ergosterol (a provitamin D2 precursor), and chitin comprising the fungal cell wall. Bioavailability of β-glucans from fungal sources is partially limited by the chitin matrix encasing polysaccharide chains, and processing methods such as hot water extraction, enzymatic digestion, or alcohol extraction significantly influence the quantity and molecular weight distribution of bioavailable β-glucan fractions.
How It Works
Mechanism of Action
The primary immunomodulatory mechanism of Trametes hirsuta is attributed to its β-glucan polysaccharides, which bind to Dectin-1 receptors and complement receptor 3 (CR3/CD11b/CD18) on innate immune cells including macrophages, natural killer cells, and dendritic cells, triggering downstream NF-κB and MAPK signaling cascades that upregulate cytokine production including TNF-α, IL-6, and IL-12. Phenolic compounds such as gallic acid and structurally related polyphenols present in Trametes extracts function as electron donors that interrupt lipid peroxidation chain reactions and scavenge superoxide anion, hydroxyl radical, and peroxynitrite directly. The anticancer activity observed in MCF-7 cell assays is hypothesized to involve apoptosis induction through mitochondrial pathway disruption and reactive oxygen species accumulation within cancer cells, though the specific molecular targets of T. hirsuta's bioactive fractions have not yet been fully characterized. Antispasmodic activity observed in animal models likely involves antagonism of muscarinic acetylcholine receptors or direct modulation of calcium channel activity in smooth muscle, consistent with the pharmacological profile of flavonoid-rich plant and fungal extracts.
Clinical Evidence
No human clinical trials have been conducted on Trametes hirsuta as of the available published literature, making it impossible to report effect sizes, confidence intervals, or patient-level outcomes for this species specifically. The most quantified preclinical findings include 59.43% antispasmodic activity at 300 mg/kg in an animal model and greater than 80% MCF-7 cancer cell inhibition for two distinct extract fractions in vitro, both of which represent hypothesis-generating rather than practice-informing data. Antibacterial activity against Staphylococcus aureus has been documented qualitatively but has not been quantified with minimum inhibitory concentration values or benchmarked against standard antibiotics in a systematic comparison. Until Phase I safety studies and controlled efficacy trials in humans are completed, all therapeutic applications remain speculative and grounded only in preliminary experimental evidence.
Safety & Interactions
No formal toxicological studies, maximum tolerated dose studies, or adverse event profiles have been published specifically for Trametes hirsuta in humans, and the safety classification of this species for human consumption remains unestablished in regulatory or pharmacopoeial frameworks. One research publication characterizes T. hirsuta as a candidate source of bioactive compounds with potential for fewer adverse effects compared to synthetic drugs, but this is an inferential statement rather than safety data derived from controlled exposure studies. Drug interactions have not been empirically studied; however, given the immunomodulatory β-glucan content, theoretical caution is warranted in individuals taking immunosuppressant medications such as calcineurin inhibitors or corticosteroids, as enhanced immune activation could theoretically counteract therapeutic immunosuppression. Use during pregnancy and lactation is not recommended due to the complete absence of reproductive safety data, and individuals with known mushroom allergies or autoimmune conditions should consult a qualified healthcare provider before use.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Trametes hirsuta (Wulfen) LloydCoriolus hirsutusPolyporus hirsutusHairy Bracket FungusHairy Turkey Tail
Frequently Asked Questions
What are the main health benefits of Trametes hirsuta?
Trametes hirsuta demonstrates antioxidant, immunomodulatory, antispasmodic, and anticancer activities in preclinical research, attributed primarily to its β-glucan polysaccharides and phenolic compounds including gallic acid and flavonoids. The most quantified findings include 92.3% inhibition of MCF-7 breast cancer cells in vitro and 59.43% antispasmodic activity at 300 mg/kg in an animal model, though no human clinical trials have confirmed these effects.
How does Trametes hirsuta differ from Trametes versicolor (turkey tail)?
While both Trametes hirsuta and Trametes versicolor are closely related white-rot polypore fungi sharing similar β-glucan and polyphenol profiles, T. versicolor has been far more extensively studied clinically and is the source of the commercially developed immunomodulatory preparations PSK (Krestin) and PSP used in cancer adjuvant therapy in Japan and China. T. hirsuta lacks the depth of human clinical evidence available for T. versicolor, making it a less validated option despite comparable in vitro bioactivity signals.
Is Trametes hirsuta safe to consume as a supplement?
No formal human safety studies, toxicological assessments, or adverse event data have been published for Trametes hirsuta, so its safety profile for human supplementation cannot be confirmed from peer-reviewed evidence. Individuals taking immunosuppressant medications, those with autoimmune conditions, pregnant or breastfeeding women, and individuals with known mushroom allergies should avoid use or consult a healthcare provider before considering any T. hirsuta preparation.
What is the recommended dosage of Trametes hirsuta?
No validated human dosage has been established for Trametes hirsuta based on clinical trial data. The only pharmacological dosing reference available is from an animal antispasmodic study using 150–300 mg/kg body weight of ethanolic extract, which cannot be directly extrapolated to human supplemental doses without pharmacokinetic bridging studies and safety data.
What bioactive compounds are responsible for Trametes hirsuta's activity?
The primary bioactive constituents of Trametes hirsuta include β-(1,3)/(1,6)-glucan polysaccharides, which drive immunomodulatory effects via Dectin-1 receptor activation, and phenolic compounds such as gallic acid and structurally related flavonoids that provide antioxidant activity through free radical scavenging mechanisms. Minor constituents including saponins, anthraquinones, and ligninolytic enzymes such as laccase also contribute to its broad bioactivity profile observed in laboratory studies.
Does Trametes hirsuta interact with immunosuppressant medications?
Trametes hirsuta's immunomodulatory properties, driven by its β-glucans activating Dectin-1 receptors on immune cells, may potentially interfere with immunosuppressant drugs used after organ transplants or for autoimmune conditions. Individuals taking immunosuppressive medications should consult their healthcare provider before adding Trametes hirsuta supplements to avoid counteracting the intended therapeutic effects. The degree of interaction varies based on extract concentration and individual immune status.
What is the most bioavailable form of Trametes hirsuta supplement?
Hot water extracts and dual-extraction methods (combining hot water and ethanol) are considered most bioavailable for Trametes hirsuta, as they effectively solubilize both water-soluble polysaccharides (β-glucans) and alcohol-soluble compounds (phenolics and flavonoids). Standardized extracts with documented β-glucan content (typically 20–40%) and polyphenol levels provide more consistent bioavailability than raw fruiting body powder. Extraction temperature and solvent ratios significantly impact the concentration of active immunomodulatory and antioxidant compounds available for absorption.
Who should avoid Trametes hirsuta supplementation?
Individuals with autoimmune diseases (such as lupus, rheumatoid arthritis, or multiple sclerosis) should avoid Trametes hirsuta due to its potent immune-stimulating effects, which may exacerbate autoimmune symptoms. Those scheduled for surgery or on immunosuppressive therapy, as well as pregnant and nursing women (due to limited safety data), should consult a healthcare provider before use. People with mushroom allergies or mold sensitivities may experience adverse reactions to fungal extracts.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w trametes-hirsuta-trametes-hirsuta-wulfen-lloyd curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
